Loading
Lille haematologist and President of LYSA, the French-Belgian lymphoma cooperative group, who led the RELEVANCE trial of chemotherapy-free therapy in follicular lymphoma.
Franck Morschhauser is President of LYSA, the Lymphoma Study Association, and Professor of Haematology at Lille University Hospital, France. He was first author of the RELEVANCE trial comparing rituximab plus lenalidomide with rituximab-chemotherapy in untreated follicular lymphoma. His research spans novel immunotherapies and targeted agents across indolent and aggressive B-cell lymphomas.
| Title | Journal | Year |
|---|---|---|
| Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma | New England Journal of Medicine | 2018 |
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma.
Shares Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma, haematology.
Shares Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma.
Shares Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma.
Shares Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma.
Shares Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma.
Shares Diffuse large B-cell lymphoma and the tags leadership, clinician-scientist, lymphoma.
Shares the tags clinician-scientist, lymphoma, haematology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/